Morphine Sulfate | Health Canada | Drug Product Database | DPD | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Morphine Sulfate
Canada

PharmaCompass Sponsored Ads

Contact Supplier

Temad Morphine Sulfate

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Morphine Sulfate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 12 USDMF, 6 CEP/COS, 4 KDMF, 14 NDC API, 12 Listed Suppliers, $ API Reference Price

23 API Suppliers
12 USDMF
6 CEP/COS
4 KDMF
14 NDC API
12 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

627 FDF Dossiers, 223 FDA Orange Book, 169 Europe, 47 Canada, 106 Australia, 20 South Africa, 62 Listed Dossiers

627 FDF Dossiers
223 FDA Orange Book
169 Europe
47 Canada
106 Australia
20 South Africa
62 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 200MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, INJECTABLE;INJECTION - 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAMUSCULAR - 10MG/0.7ML (10MG/0.7ML), INJECTABLE;INJECTION - 10MG/ML, INJECTABLE;INJECTION - 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - 2MG/ML, INJECTABLE;INJECTION - 4MG/ML, INJECTABLE;INJECTION - 50MG/ML, INJECTABLE;INJECTION - 8MG/ML, CAPSULE, EXTENDED RELEASE;ORAL - 100MG, CAPSULE, EXTENDED RELEASE;ORAL - 10MG, CAPSULE, EXTENDED RELEASE;ORAL - 130MG, CAPSULE, EXTENDED RELEASE;ORAL - 150MG, CAPSULE, EXTENDED RELEASE;ORAL - 200MG, CAPSULE, EXTENDED RELEASE;ORAL - 20MG, CAPSULE, EXTENDED RELEASE;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, CAPSULE, EXTENDED RELEASE;ORAL - 50MG, CAPSULE, EXTENDED RELEASE;ORAL - 60MG, CAPSULE, EXTENDED RELEASE;ORAL - 70MG, CAPSULE, EXTENDED RELEASE;ORAL - 80MG, TABLET, EXTENDED RELEASE;ORAL - 100MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, TABLET, EXTENDED RELEASE;ORAL - 15MG, TABLET, EXTENDED RELEASE;ORAL - 30MG, TABLET, EXTENDED RELEASE;ORAL - 60MG, SOLUTION;ORAL - 100MG/5ML, SOLUTION;ORAL - 10MG/5ML, SOLUTION;ORAL - 20MG/5ML, TABLET;ORAL - 15MG, TABLET;ORAL - 30MG, CAPSULE, EXTENDED RELEASE;ORAL - 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 20MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, EXTENDED RELEASE;ORAL - 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 100MG
TABLET, EXTENDED RELEASE;ORAL - 15MG
TABLET, EXTENDED RELEASE;ORAL - 200MG
TABLET, EXTENDED RELEASE;ORAL - 30MG
TABLET, EXTENDED RELEASE;ORAL - 60MG
INJECTABLE;INJECTION - 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;INTRAMUSCULAR - 10MG/0.7ML (10MG/0.7ML)
INJECTABLE;INJECTION - 10MG/ML
INJECTABLE;INJECTION - 15MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - 2MG/ML
INJECTABLE;INJECTION - 4MG/ML
INJECTABLE;INJECTION - 50MG/ML
INJECTABLE;INJECTION - 8MG/ML
CAPSULE, EXTENDED RELEASE;ORAL - 100MG
CAPSULE, EXTENDED RELEASE;ORAL - 10MG
CAPSULE, EXTENDED RELEASE;ORAL - 130MG
CAPSULE, EXTENDED RELEASE;ORAL - 150MG
CAPSULE, EXTENDED RELEASE;ORAL - 200MG
CAPSULE, EXTENDED RELEASE;ORAL - 20MG
CAPSULE, EXTENDED RELEASE;ORAL - 30MG
CAPSULE, EXTENDED RELEASE;ORAL - 40MG
CAPSULE, EXTENDED RELEASE;ORAL - 50MG
CAPSULE, EXTENDED RELEASE;ORAL - 60MG
CAPSULE, EXTENDED RELEASE;ORAL - 70MG
CAPSULE, EXTENDED RELEASE;ORAL - 80MG
TABLET, EXTENDED RELEASE;ORAL - 100MG
TABLET, EXTENDED RELEASE;ORAL - 15MG
TABLET, EXTENDED RELEASE;ORAL - 30MG
TABLET, EXTENDED RELEASE;ORAL - 60MG
TABLET, EXTENDED RELEASE;ORAL - 15MG
TABLET, EXTENDED RELEASE;ORAL - 30MG
TABLET, EXTENDED RELEASE;ORAL - 60MG
SOLUTION;ORAL - 100MG/5ML
SOLUTION;ORAL - 10MG/5ML
SOLUTION;ORAL - 20MG/5ML
TABLET;ORAL - 15MG
TABLET;ORAL - 30MG
CAPSULE, EXTENDED RELEASE;ORAL - 100MG;4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 20MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 30MG;1.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 50MG;2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 60MG;2.4MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE, EXTENDED RELEASE;ORAL - 80MG;3.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

3 Evonik, 4 Rochem International Inc, 17 SPI Pharma, 2 Seqens, 20 DKSH, 1 Jai Radhe Sales, 2 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 4 Boai NKY Pharmaceuticals Ltd, 13 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 15 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 36 BASF, 1 Bioplus Life Sciences, 2 Clariant, 17 Corel Pharma Chem, 5 DFE Pharma, 4 Finar, 12 Gangwal Chemicals, 16 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 3 Novo Excipients, 2 Pharmatrans-Sanaq, 9 Pluviaendo, 2 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 15 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 The Dow Chemical Company, 1 Ulanqab Kema New Material, 2 Valens Pharmachem, 2 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

109 Fillers, Diluents & Binders, 78 Coating Systems & Additives, 52 Controlled & Modified Release, 41 Direct Compression, 39 Thickeners and Stabilizers, 35 Topical, 34 Solubilizers, 33 Parenteral, 28 Taste Masking, 27 Granulation, 27 Film Formers & Plasticizers, 22 Co-Processed Excipients, 22 Lubricants & Glidants, 16 Chewable & Orodispersible Aids, 13 Disintegrants & Superdisintegrants, 11 Emulsifying Agents, 9 Empty Capsules, 9 API Stability Enhancers, 9 Rheology Modifiers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

109 Fillers, Diluents & Binders
78 Coating Systems & Additives
52 Controlled & Modified Release
41 Direct Compression
39 Thickeners and Stabilizers
35 Topical
34 Solubilizers
33 Parenteral
28 Taste Masking
27 Granulation
27 Film Formers & Plasticizers
22 Co-Processed Excipients
22 Lubricants & Glidants
16 Chewable & Orodispersible Aids
13 Disintegrants & Superdisintegrants
11 Emulsifying Agents
9 Empty Capsules
9 API Stability Enhancers
9 Rheology Modifiers
6 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

5 DATA COMPILATION #PharmaFlow, 119 NEWS #PharmaBuzz

5 DATA COMPILATION #PharmaFlow
119 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 186 Finished Drug Prices

1 US Medicaid Prescriptions
186 Finished Drug Prices

MARKET PLACE

16 APIs, 19 FDF Dossiers

16 APIs
19 FDF Dossiers

PATENTS & EXCLUSIVITIES

88 US Patents, 4 US Exclusivities, 26 Health Canada Patents

88 US Patents
4 US Exclusivities
26 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 4 USP, 7 Others

2 EDQM
4 USP
7 Others

$ API Ref.Price (USD/KG) : 15,454 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

47 All

01 6ETHYPHARM INC

02 4BGP PHARMA ULC

03 2FRESENIUS KABI CANADA LTD

04 3JAMP PHARMA CORPORATION

05 2PALADIN PHARMA INC.

06 9PURDUE PHARMA

07 12SANDOZ CANADA INCORPORATED

08 3STERIMAX INC

09 1STERINOVA INC.

10 5TEVA CANADA LIMITED

filter Active Ingredients Reset all filters

47 All

01 47MORPHINE SULFATE

filter Dosage Form Reset all filters

47 All

01 6CAPSULE (EXTENDED RELEASE)

02 4CAPSULE (SUSTAINED-RELEASE)

03 3LIQUID

04 13SOLUTION

05 2TABLET

06 15TABLET (EXTENDED-RELEASE)

07 4TABLET (IMMEDIATE RELEASE)

filter Brand Name Reset all filters

47 All

01 4KADIAN

02 6M-ESLON

03 1MORPHINE HP 50

04 2MORPHINE LP EPIDURAL

05 1MORPHINE SULFATE INJ 10MG/ML USP

06 1MORPHINE SULFATE INJ 15MG/ML USP

07 3MORPHINE SULFATE INJECTION

08 1MORPHINE SULFATE INJECTION BP

09 2MORPHINE SULFATE INJECTION EPIDURAL

10 1MORPHINE SULFATE INJECTION SDZ

11 2MORPHINE SULFATE INJECTION USP

12 2MORPHINE SULFATE INJECTION, USP

13 5MS CONTIN

14 4MS.IR

15 5SANDOZ MORPHINE SR

16 1STATEX TAB 10MG

17 1STATEX TAB 5MG

18 5TEVA-MORPHINE SR

Veranova Morphine Sulfate

List of Suppliers

Product Main Page

01

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 15MG

Packaging : 20/50

Approval Date :

Application Number : 2177749

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

02

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 200MG

Packaging : 20/50

Approval Date :

Application Number : 2177757

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

03

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 30MG

Packaging : 20/50

Approval Date :

Application Number : 2019949

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

04

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 100MG

Packaging : 20/50

Approval Date :

Application Number : 2019965

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

05

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 60MG

Packaging : 20/50

Approval Date :

Application Number : 2019957

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

06

ETHYPHARM INC

CPhI WW Frankfurt

Ethypharm is an international Pharma company with European roots manufacturing and commercializing essential drugs all over the world.

Contact Supplier

Contact Supplier

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : M-ESLON

Dosage Form : CAPSULE (EXTENDED RELEASE)

Dosage Strength : 10MG

Packaging : 20/50

Approval Date :

Application Number : 2019930

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Product Web Link

Digital Content

07

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : KADIAN

Dosage Form : CAPSULE (SUSTAINED-RELEASE)

Dosage Strength : 20MG

Packaging : 100

Approval Date :

Application Number : 2184435

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : KADIAN

Dosage Form : CAPSULE (SUSTAINED-RELEASE)

Dosage Strength : 50MG

Packaging : 100

Approval Date :

Application Number : 2184443

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

BGP PHARMA ULC

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : KADIAN

Dosage Form : CAPSULE (SUSTAINED-RELEASE)

Dosage Strength : 100MG

Packaging : 50

Approval Date :

Application Number : 2184451

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

PURDUE PHARMA

Fi Europe 2024

Not Confirmed

PURDUE PHARMA

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

MORPHINE SULFATE

Brand Name : MS CONTIN

Dosage Form : TABLET (EXTENDED-RELEASE)

Dosage Strength : 30MG

Packaging : 50

Approval Date :

Application Number : 2014297

Regulatory Info : Narcotic (CDSA I)

Registration Country : Canada

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?